Table 1.
Demography of patients for whom vitreous analysis was performed.
| Patient Variables | Control | Non-Reoperated a | Reoperated b |
|---|---|---|---|
| N | 18 | 18 | 18 |
| Age (mean, range) c | 69 (29–80) | 58 (39–83) | 53 (24–81) |
| Sex (M/F) d | 12/6 | 12/6 | 8/10 |
| Surgery (MH/ERM) e | 4/14 | ||
| DM type (T1D/T2D) f | 7/11 | 8/10 | |
| DM duration (mean, range) g | 24 (5–41) | 21 (1–44) | |
| Rubeosis iridis (N) h | 2 | 3 | |
| Neovascular glaucoma (N) i | 1 | 0 | |
| Preoperative laser (N) j | 16 | 16 | |
| Peroperative laser (N) k | 17 | 15 | |
| PVD (N) l | 6 | 3 | |
| Tamponade (n/a/s/c) m | 1/10/4/3 | 3/10/1/4 | |
| 2nd PPV (mean, range) n | 13 (2–48) |
a PDR cases without recurrent postoperative vitreous hemorrhage; b PDR cases reoperated due to recurrent postoperative vitreous hemorrhage; c Age is given in years; d Male/Female; e Macular hole (MH); epiretinal membrane (ERM); f type-1 diabetes (T1D); type-2 diabetes (T2D); g Duration is given in years; h Preoperative rubeosis iridis present; i Preoperative neovascular glaucoma present; j Preoperative scatter laser was present; k Preoperative scatter laser present; l Complete preoperative posterior vitreous detachment (PVD) present; m Surgical tamponade used (none/air/SF6/C3F8); n Duration until secondary PPV is given in weeks.